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Abstract
Osteomyelitis is a debilitating infectious disease of the bone. It is predominantly caused by S. aureus and is associated with
significant morbidity and mortality. It is characterised by weakened bones associated with progressive bone loss. Currently
the mechanism through which either bone loss or bone destruction occurs in osteomyelitis patients is poorly understood.
We describe here for the first time that the major virulence factor of S. aureus, protein A (SpA) binds directly to osteoblasts.
This interaction prevents proliferation, induces apoptosis and inhibits mineralisation of cultured osteoblasts. Infected
osteoblasts also increase the expression of RANKL, a key protein involved in initiating bone resorption. None of these effects
was seen in a mutant of S. aureus lacking SpA. Complementing the SpA-defective mutant with a plasmid expressing spa or
using purified protein A resulted in attachment to osteoblasts, inhibited proliferation and induced apoptosis to a similar
extent as wildtype S. aureus. These events demonstrate mechanisms through which loss of bone formation and bone
weakening may occur in osteomyelitis patients. This new information may pave the way for the development of new and
improved therapeutic agents to treat this disease.
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Introduction
The skeleton is a dynamic organ system which is constantly
being rejuvenated and remodelled [1]. Bone remodelling involves
the coordinated effort of osteoclasts and osteoblasts. Osteoclasts
drive resorption of bone by acidification and release of lysosomal
enzymes. Osteoblasts are responsible for the deposition of bone
matrix and are thought to facilitate the calcification and
mineralisation of the bone matrix. Together these cells function
to ensure healthy bone, giving strength and rigidity in the skeletal
system [2]. When pathogenic bacteria gain entry to healthy bone
this leads to a condition called osteomyelitis.
Osteomyelitis is a debilitating infectious disease of the bone
which is associated with significant morbidity and mortality [3]. It
typically develops in the distal femur and proximal tibia in
children and in adults, but any bone can be infected [4]. It is
characterised by severe inflammation and progressive bone
destruction [5]. Infection can occur as a result of haematogeneous
spread or from a contiguous source secondary to an open injury to
bone caused by trauma, bone surgery or joint replacement [6]. As
part of the infectious process dead or dying bone can detach from
healthy bone forming an island surrounded by a ring of sclerosis,
which in turn leads to the development of an independent focus of
infection [7]. In acute and chronic disease there is some degree of
uncontrolled bone remodelling which often leads to an associated
deformity [8]. Treatment of osteomyelitis involves aggressive
antibiotic therapy which is often coupled with surgical debride-
ment of infected tissue [4]. Antibiotic therapy is often unsuccessful
because developing sequestra are typically avascular [3]. Thus
antibiotics and inflammatory cells cannot reach the infected area
and treatment often fails. Treatment is also compromised by the
emergence of antibiotic resistance [9].
S. aureus permanently colonizes the anterior nares of the nostrils
of about 20% of the population and is transiently associated with
the rest [10]. Colonisation is a risk factor for developing infection.
Until recently S. aureus was regarded as an extracellular pathogen.
However it is clear that the organism can adhere to and become
internalized by a variety of host cells [6], including osteoblasts
[11], and that this is likely to be important in disease pathogenesis.
Uptake is promoted by fibronectin binding proteins that capture
fibronectin and use it as a bridge between bacteria and the a5b1
integrin [12]. Integrin clustering results in signalling that lead to
bacterial uptake into phagocytic vesicles. Once internalized
bacteria can escape the phagosome and cause necrosis [13]. Slow
growing variants (called small colony variants) often emerge
allowing the bacteria and the infection to persist [14].
Protein A (SpA) is an important virulence factor of S. aureus. It
binds to a variety of ligands including the Fc region of IgG [15],
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18748
von Willebrand factor [16], tumour necrosis factor receptor-1
(TNFR-1) [17], the Fab-heavy chains of the Vh3 subclass [18] and
the epidermal growth factor receptor (EGFR)[19]. Five ligand
binding domains lie at the N-terminus followed by regions Xc and
Xr that allow the protein to span the cell wall. It is covalently
attached to peptidoglycan following sortase cleavage of the
LPXTG motif at the C-terminus [20]. Each binding domain
comprises a triple helical bundle [21]. The IgG Fc region binds to
residues exposed on the face formed by helices I and II. TNFR-1
also binds to this face but there are some differences in the residues
of SpA that are involved. In particular, leucine 17 is crucial for
binding to IgG but not for TNFR-1 binding [17].
Although current epidemiological data suggest that S. aureus is
responsible for greater than 80% of osteomyelitis cases there is a
distinct paucity of information surrounding the mechanisms that S.
aureus uses to weaken and trigger bone destruction. While previous
studies have clearly identified mechanisms through which S. aureus
can become internalised into osteoblasts, thus evading the immune
system and avoiding antibiotic attack, these studies failed to
identify mechanisms that lead to bone destruction. This study was
undertaken to investigate the mechanism though which S. aureus
binds to and triggers localised bone destruction. Understanding
these mechanisms may leads to the development of new and
improved therapeutic agents to treat this disease.
Results
S. aureus binding to osteoblasts is mediated by SpA
The contribution of cell surface molecules to the ability of
S.aureus to support adherence to osteoblasts was investigated using
isogenic mutants. It should be noted that strain Newman does not
express fibronectin binding proteins so these strains are unlikely to
be internalized rapidly. Mutants defective in several surface
proteins previously shown to be involved in host recognition were
immobilized and the ability of osteoblasts to adhere to the bacteria
was measured. Mutants defective in expression of clumping factors
A (ClfA) and B (ClfB), and serine asparate repeat proteins SdrC,
SdrD and SdrE expression had no effect on osteoblast binding
(Fig 1A, P=NS) whereas a mutant defective in SpA bound
significantly less than the wildtype (Fig 1A, P,0.05). In order to
confirm that SpA was involved in binding osteoblasts, a mutant of
S. aureus Newman was complemented with a multicopy plasmid
carrying the spa gene, pCU1spa. After growth, the expression of
protein A was detected by western immunoblotting (data not
shown). Complementation of the S. aureus SpA mutant with
pCU1spa resulted in attachment to osteoblasts to a similar extent
of that of the wildtype S. aureus Newman (Fig 1B, P=NS to the
wildtype Newman control).
In order to determine if other strains of S. aureus, and in
particular those expressing FnBPs, could bind osteoblasts and to
examine the role of SpA, strains SH1000 and 8325-4 along with
their isogenic spa-deficient mutants were tested. In both cases a
significant reduction in osteoblast binding was observed (Fig 1C,
P,0.01 and Fig 1D, P,0.005, respectively). Finally, to confirm
the ability of SpA to interact with osteoblasts, the purified protein
was immobilized and was shown to support binding of the
osteoblasts (Fig 1E, P,0.01). As a control the recombinant A
domain of clumping factor A did not promote attachment.
S. aureus binds to osteoblast Tumour Necrosis Factor
Receptor 1
SpA is a multifunctional protein that has been shown to bind a
number of ligands including IgG and Tumour Necrosis Factor
Receptor1 (TNFR-1). Osteoblasts express high levels of TNFR-1.
We investigated if SpA expressed by S. aureus could support
binding to osteoblasts via TNFR-1. We used a strain of S. aureus
Newman that expressed a variant of SpA where leucine 17 was
substituted with an alanine in each of the five ligand binding
domains. This substitution completely abolished IgG binding, but
did not affect binding to TNFR-1 (Gomez et al., 2006).
Immunoblotting was performed to show that the SpA variant
L17A did not bind IgG. In contrast, Newman pCU1spa reacted
with IgG in the blot. In control blots anti-SpA IgY bound to SpA
from wildtype Newman, Newman pCU1spa and Newman
pCU1spa L17A (Fig 2A). S. aureus Newman pCU1spa promoted
adherence of osteoblasts equally as well as the Newman expressing
wildtype SpA (9961% of wildtype control, P =NS, n= 5).
Furthermore, osteoblast-binding to Newman pCU1spa was
significantly reduced by pretreatment of osteoblasts with a
monoclonal anti-TNFR-1 IgG antibody (Fig 2B, P,0.05). These
results indicate that immobilized S. aureus cells can support binding
of cultured osteoblasts mediated by the interaction between SpA
and TNFR-1.
S. aureus SpA inhibits proliferation of osteoblasts
Given the observation that S. aureus SpA binds to osteoblasts we
next investigated if SpA had any effect on osteoblast survival or
proliferation. Live S. aureus can use nutrients in tissue culture
media to divide. This process will starve osteoblasts of essential
nutrients necessary for their growth. To address this we fixed S.
aureus in a mild formaldehyde solution aimed to maintain bacterial
cell integrity yet stunt their growth. This fixation step failed to
have any effect on the SpA protein as determined by western blot
(Fig 3A). Formaldehyde-fixed S. aureus Newman was added to
osteoblasts and proliferation determined after 24 and 48 hrs. In
the absence of S. aureus, osteoblasts proliferated as expected.
Addition of S. aureus Newman Spa+ ablated proliferation (Fig 3B,
P,0.01). A mutant defective in SpA did not prevent proliferation
(P=NS to uninfected osteoblasts). Complementation of the S.
aureus mutant with pCU1spa restored the inhibitory effect to the
same level as wild type (P,0,01). Finally, addition of purified
protein A to osteoblasts also prevented proliferation (P,0.01).
These results suggest that S. aureus SpA binds to osteoblasts and
triggers a signal transduction pathway that inhibits osteoblast
proliferation.
S. aureus induces osteoblast apoptosis
It has been reported in the literature that S. aureus can induce
apoptosis in osteoblasts however the mechanism was not
elucidated [22,23]. We next investigated if S. aureus SpA binding
to osteoblasts is responsible for inducing apoptosis. Apoptosis was
first determined by measuring the amount of caspase 3 cleavage
following incubation of cultured osteoblasts with formalin-treated
S. aureus cells after a 24 hour period. Caspase 3 is a downstream
effector caspase important in death receptor apoptotic mecha-
nisms. In the absence of S. aureus, caspase 3 cleavage was minimal.
However, after incubation with wildtype S. aureus Newman,
caspase 3 activity was significantly increased, indicating that the
osteoblasts were undergoing apoptosis (Fig 4A, P,0.01). No
increase in caspase-3 cleavage occurred after addition of the S.
aureus mutant defective in SpA (P=NS compared to the uninfected
osteoblasts). Complementation with pCU1spa induced caspase 3
activity (P,0.01). Finally, addition of purified SpA to osteoblasts
also increased caspase 3 activity (data not shown, P,0.05, n= 5).
Apoptosis was also detected by measuring the amount of FITC-
Annexin V binding following incubation of cultured osteoblasts
with formalin-treated S. aureus cells after a 24 hour period. In the
absence of S. aureus 40% of osteoblasts appeared to bind Annexin
Staphylococcus aureus Induced Osteomyelitis
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V. Addition of S. aureus Newman to the osteoblasts led to a
significant increase in Annexin V binding (Fig 4B+C, P,0.05). In
contrast, addition of the S. aureus mutant defective in SpA failed to
induce apoptosis above the uninfected levels (P =NS). Addition of
S. aureus pCU1spa to the osteoblasts induced significant apoptosis
(P,0.001). S. aureus pCU1spa induced significantly more apoptosis
than the wildtype S. aureus strain (P,0.005).
S. aureus inhibits mineralisation of osteoblasts.
Following matrix deposition, osteoblasts facilitate the calcifica-
tion and mineralisation of bone matrix thereby ensuring strength
and rigidity to the skeletal system. We next investigated the effect
of S. aureus on the mineralisation of osteoblasts. Mineralisation
typically begins between day 7–10 and can be detected by staining
the phosphates and calcium-rich deposits on the osteoblasts.
Representative images obtained by brightfield microscopy showing
staining for phosphates (von Kossa) from day 21 is shown in Fig 5A
and for calcium deposition (Alizarin red) is shown in Fig 5B.
Uninfected osteoblasts showed signs of both phosphate (Fig 5A)
and calcium deposition (Fig 5B). Addition of either S. aureus
Newman or S. aureus complemented with pCU1Spa prevented both
phosphate (Fig 5A) and calcium deposition (Fig 5B). Critically,
osteoblasts showed signs of both phosphate (Fig 5A) and calcium
deposition (Fig 5B) when S. aureus SpA mutant was added.
Quantification of the calcium deposition (alizarin red staining)
supported these results demonstrating that over a 21 day period
osteoblasts from both the uninfected and S. aureus SpA mutant
stained for calcium deposition similarly (Fig 5C, P=NS), whereas
S. aureus Newman and S. aureus complemented with pCU1Spa
failed to do so (Fig 5C, P,0.01 and P,0.001, respectively).
Figure 1. Protein A is involved in binding of Staphylococcus aureus to osteoblasts. Osteoblasts were allowed adhere to immobilised
wildtype S. aureus and isogenic mutants (16109 cells/ml), (A+B) strain Newman, (C) strain SH1000, (D) strain 8325-4 or (E) purified protein A or
recombinant ClfA(50 mg/ml) for 45 mins at 37uC. Adhesion was determined by measuring the intracellular enzyme alkaline phosphatase content at
405 nm in a microplate reader. *P,0.05, **P,0.01, n = 7.
doi:10.1371/journal.pone.0018748.g001
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S. aureus induced RANKL expression in osteoblasts
RANKL is a key molecule involved in bone remodeling. Once
expressed on osteoblasts it initiates bone resorption. Previous
studies have shown that RANKL is upregulated in patients with
staphylococcal osteomyelitis. We therefore investigated if S. aureus
SpA leads to RANKL expression by osteoblasts. Quantitative
analysis of membrane bound RANKL expression on osteoblasts
after 24 hrs demonstrated that in uninfected osteoblasts a low level
of RANKL was expressed. Addition of S. aureus Newman
significantly increased RANKL expression following 24 hrs
(Fig 6A. P,0.0001). Addition of the S. aureus SpA mutant failed
to express significant levels of membrane bound RANKL
compared to the uninfected sample (P=NS). However, comple-
mentation of the S. aureus mutant with pCU1spa led to significant
expression of membrane bound RANKL (P,0.0001).
Osteoprotegerin is a natural inhibitor of RANKL. By binding
RANKL, osteoprotegrin prevents transcription via NF-kB and
activation of osteoclasts, thereby preventing bone resorption.
When RANKL expression is high osteoprotegrin levels are low
and vice versa. Therefore we investigated this inverse relationship
Figure 2. Staphylococcus aureus SpA binds to osteoblast tumour
necrosis factor receptor 1. (A) S. aureus Newman, Newman pCU1spa
and Newman pCU1spa L17A were lysed, separated on 7.5% SDS-PAGE
gels, electroblotted onto PDVF membranes. Membranes were probed
with either a nonspecific IgG or anti-SpA IgY antibody. Protein bands
were detected using species specific horseradish peroxidase-conjugat-
ed secondary antibody and chemiluminescence. (B) Osteoblasts (56105
cells/ml) were preincubated with either isotype control antibody or
inhibitory monoclonal antibody against TNFR-1 for 15 mins prior to
addition to S. aureus Newman pCU1spa L17A. Adhesion was
determined by measuring the intracellular enzyme alkaline phospha-
tase content at 405 nm in a microplate reader. *P,0.05, n = 7.
doi:10.1371/journal.pone.0018748.g002
Figure 3. Staphylococcus aureus lacking SpA does not inhibit
osteoblast proliferation. (A) Live or formaldehyde fixed S. aureus
Newman was lysed in RIPA buffer containing 1 X protease inhibitor
cocktail on ice for 10 minutes and probed with anti-protein A IgY
antibodies. Protein bands were detected using species specific
horseradish peroxidase-conjugated secondary antibody and chemilu-
minescence. (B) Osteoblasts (56105 cells/ml) were preincubated with
either control buffer or formaldehyde fixed S. aureus Newman, Newman
SpA deficient or Newman pCU1spa (16109 cells/ml) or purified protein
A (50 mg/ml) for a total period of 21 days. After days 7, 14 and 21
osteoblasts were removed by trypsinization and proliferation was
determined by counting cells on a haemocytometer. *P,0.01, **P =NS,
n = 5.
doi:10.1371/journal.pone.0018748.g003
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by measuring osteoprotegrin in infected and uninfected osteo-
blasts. Consistent with these findings osteoprotegrin was high in
uninfected osteoblasts and significantly lower in S. aureus infected
osteoblasts following 24 hrs (Fig 6B, P,0.001). Osteoprotegrin
levels were high in cells exposed to the S. aureus SpA mutant and
low in the S. aureus complemented with pCU1Spa (P,0.001).
Collectively these results suggest that SpA binding to the
osteoblasts is responsible for RANKL expression leading to
activation of osteoclasts and bone breakdown.
Discussion
Bone is normally resistant to infection. However trauma,
surgery to the skeleton or placement of a foreign body such as
an orthopaedic implant may expose this otherwise sterile
environment to infection. S. aureus is a common human pathogen
which lives harmlessly on the skin and mucous membranes of
healthy individuals. It is isolated from more than 80% of patients
with bone infection or osteomyelitis [13]. Upon exposure to the
bone, S. aureus induces a severe inflammatory response followed by
progressive bone destruction and loss of the vasculature. As a
result, sections of dead bone separate themselves from the healthy
bone forming a sequestra [7]. This area of dead infected tissue is
inaccessible to immune cells or to antibiotics, leading to persistent
chronic infection. This is further complicated by the rapid
emergence of strains of S. aureus that are resistant to multiple
antibiotics which makes treatment of this disease very difficult [3].
A better understanding of the interactions between S. aureus and
Figure 4. Staphylococcus aureus lacking SpA does not trigger osteoblast apoptosis. (A) Osteoblasts (56105 cells/ml) were preincubated
with either control buffer or formaldehyde fixed S. aureus Newman (16109 cells/ml) for 24 hrs. Osteoblasts are removed, lysed and incubated with
caspase 3 substrate (DEVD-pNA) for 1 hr at 37uC. Caspase 3 cleavage was measured at 405 nm in a microplate reader. (B+C) To measure Annexin V
binding pelleted osteoblasts were re-suspended in 100 ml of FITC-Annexin V antibody. Suspensions were incubated in the dark for 15 min at RT and
analysed by flow cytometry. *P,0.01, **P,0.05, n = 5.
doi:10.1371/journal.pone.0018748.g004
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the bone may aid in the development of novel therapeutics to treat
this disease.
Previous reports demonstrated that S. aureus is capable of
invading osteoblasts from human, murine and chicken sources in
both culture and in vivo [24]; [25]; [26]. Invasion is dependent on
the S. aureus fibronectin binding proteins FnbpA and FnbpB which
bind to the extracellular matrix protein fibronectin and serves as a
bridging molecule to integrin a5b1 [12]. In the absence
fibronectin or using mutants deficient in FnbpA and FnbpB, S.
aureus invades osteoblasts very poorly. Interestingly bacteria still
adhere to the osteoblast surface [11] even in the absence of FnbpA
and FnbpB. Thus, S. aureus is also capable of directly interacting
with osteoblasts in the absence of extracellular matrix proteins
such as fibronectin.
S. aureus expresses several components that are capable of
interacting with osteoblasts. A major virulence factor known to
promote evasion of/or interference with the host immune system
is capsular polysaccharides expressed on the bacterial cell surface
[27]; [28]. Deletion of capsule from S. aureus Newman or using the
capsule negative strain SH1000 failed to have any effect on
binding, suggesting that the polymeric carbohydrates that are
found in the capsule do not mediate attachment to osteoblasts
(data not shown). S. aureus owes much of its pathogenicity to an
array of cell wall-anchored surface proteins. These adhesins
facilitate binding to various matrix proteins or host cells [29].
SpA is one of the most prevalent cell wall proteins on S. aureus
and appears to play an important role in the success of S. aureus as
a human pathogen [10]; [16]. By binding the Fc portion of
Figure 5. Staphylococcus aureus induces RANKL and inhibits OPG in osteblasts. S. aureus (16109 cells/ml) was added to the osteoblasts for
24 hrs. Two hundred micro litres of the RIPA buffer was added to each well resulting protein was removed and centrifuged at610,000 g for 2
minutes. (A) RANKL or (B) OPG was detected using an ELISA kit. *P,0.001, **P,0.0001, n = 3.
doi:10.1371/journal.pone.0018748.g005
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immunoglobulin, SpA assists S. aureus in evasion of phagocytosis by
neutrophils [30]. SpA also binds to von Willebrand factor which
may play a role in supporting platelet adhesion in the early stages
of thrombosis[16]. In addition, Gomez and colleagues demon-
strated that SpA binds to the EGFR to regulate TNFR1
availability[19]. Deletion of SpA in several different strains of S.
aureus (Newman, SH1000, 8325-4) significantly reduced binding to
osteoblasts. Complementing the SpA mutant with the pCU1spa
plasmid restored binding.
Recently, S. aureus SpA was shown to bind directly to TNFR-1
in lung epithelial cells resulting in proinflammatory signalling in
the pathogenesis of staphylococcal pneumonia[17]. Osteoblasts
also express high levels of the TNFR-1[31] and engagement with
its ligand TNFa has been implicated in a wide spectrum of bone
diseases including osteoporosis and rheumatoid arthritis[32]. Here
we demonstrate that inhibition of TNFR-1 on osteoblasts
significantly reduced binding to S. aureus. These results suggest
that SpA maybe binding to the osteoblast TNFR-1, however
additional experiments using TNFR-1 null mice or siRNA to
reduce the receptor are required to confirm this.
TNFR-1 is known as a death receptor because its engagement
triggers a series of events that culminates in apoptosis [33]. Several
reports have demonstrated that S. aureus can induce apoptosis in
osteoblasts [22,23]. However the mechanism by which this occurs
has not yet been elucidated. Caspase 3 is a key component of the
proteolytic cascade that leads to apoptosis which is typically
followed by membrane blebbing. Active caspase 3 and extrusion of
annexin V (as a measure of membrane blebbing) was detected in
the uninfected control osteoblasts and is most likely due to
apoptosis and cell turnover in the in vitro osteoblast tissue culture
system. Consistent with previous observations, when osteoblasts
were exposed to S. aureus, caspase 3 and annexin V were
significantly increased [23]. The SpA mutant yielded similar
results to the uninfected osteoblasts. The complemented mutant or
addition of purified protein A increased caspase 3 and annexin V
in osteoblasts to levels similar to S. aureus Newman. Previous results
demonstrated that S. aureus a-toxin induced apoptosis in Jurkat
cells via the Bcl-2-controlled mitochondrial death pathway which
involves caspase 3 [34] However this mechanism is not playing a
role in these experiments as the S. aureus cells are formalin-fixed
and cannot produce a-toxin. These results therefore suggest that S.
aureus SpA binds to osteoblasts, possibly through an interaction
with the death receptor TNFR-1 which induces caspase 3
activation and membrane blebbing with an end point of apoptosis.
S. aureus-induced apoptosis is not unique to osteoblasts as
endothelial and epithelial cells undergo apoptosis following S.
aureus infection [35–37].
Mineralisation is a process where phosphate and calcium
becomes deposited in bone[1]. This gives the bones additional
strength and rigidity. During S. aureus infection, mineralisation
(phosphate and calcium deposition) is completely inhibited.
Deletion of SpA from S. aureus allowed both phosphate and
calcium deposition. Interestingly, when TNFa binds to its receptor
it results in inhibition of bone mineralisation. These results further
suggest that engagement of the TNFR leads to a signal that
prevents mineralisation such as the one that S. aureus SpA provides.
RANKL is a homotrimeric molecule displayed on the membrane
of osteoblasts that stimulates differentiation in osteoclasts and is a
key induction molecule involved in bone resorption leading to bone
destruction[38]. Osteoprotegerin (OPG) is also produced and
released by osteoblasts and is an endogenous inhibitor of RANKL
signalling. It typically acts as a decoy receptor that binds to RANKL
and prevents its association with RANK with the net result of
preventing excessive bone destruction through activation of
osteoclasts[39]. Consistent with previous results we found that S.
aureus infection of osteoblasts led to a significant increase in RANKL
expression in their membrane[40]. The increase in RANKL is likely
to trigger osteoclast-induced bone resorption and bone destruction
and may help explain why patients with osteomyelitis have
significant bone loss. These results are consistent with the
observation that TNFa binding to TNFR-1 on osteoblasts triggers
ostoclast differentiation and subsequent bone destruction[41].
Critically, deletion of SpA from S. aureus prevented RANKL
expression, possibly because S. aureus is unable to bind to TNFR-1 to
trigger an increase in RANKL expression.
To date the mechanism by which S. aureus causes weakening of
the bones in osteomyelitis is not fully understood. Previous results
Figure 6. Staphylococcus aureus prevents osteoblast mineralisa-
tion. Osteoblasts (56105 cells/ml) were preincubated with either
control buffer or formaldehyde fixed S. aureus Newman (16109 cells/ml)
for a total period of 21 days. (A) Following a 21 day infection von kossa
stain was added to the osteoblasts to determine phosphate deposition.
Phosphate nodules are indicated by white arrows. (B) Following a 21
day infection alizarin red stain (2%) was added to the osteoblasts.
Calcium nodules are indicated by black arrows. (C) Staining was
quantified by leeching the cells of the dye and reading absorbance at
540 nm. Representative images from day 21 for both stains were
obtained using 20x bright field microscopy.. *P = NS, **P,0.05,
***P,0.01, n = 3.
doi:10.1371/journal.pone.0018748.g006
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demonstrate that osteoblasts internalise the S. aureus via an indirect
interaction between the fibronectin binding proteins that bind
fibronectin and form a bridge to osteoblast a5b1 as a result S.
aureus can evade immune responses and antibiotics. Here we
describe for the first time that the major S. aureus virulence protein,
SpA also binds directly to osteoblasts. This interaction results in
the generation of multiple signals leading to inhibition of osteoblast
proliferation, induction of osteoblast apoptosis, inhibition of
mineralisation and release of mediators capable of inducing bone
resorption via osteoclast activation (Fig 7). Given the finding that
inhibition of the TNFR1 significantly reduces binding to
osteoblasts it is tempting to suggest that this receptor plays a role
in the pathogenesis of the disease process however, additional
studies are required to confirm the role of the TNFR-1 in
mediating these responses. Regardless of this, SpA binding to
osteoblasts is an important step as it occurs in the absence of
matrix proteins and is most likely the initial event in the
development of bone infection. Results presented in this study
provides evidence for the first time that SpA is likely to play a
critical role in the success of S. aureus as a human pathogen in
osteomyelitis and is a potential novel drug target for the treatment
of this debilitating disease.
Methods
Bacterial strains and growth conditions
The Staphylococcus aureus strains used in this study are listed in
Table 1. They were grown to stationary phase at 37uC in Brain
Heart Infusion broth (Oxoid, Basingstoke, United Kingdom).
Bacteria were harvested and washed by centrifugation at 15,000 g
for 5 min and finally re-suspended in phosphate buffered saline
(PBS) pH 7.4. For all experiments, S. aureus suspensions were
adjusted to 16109 cells/ml. In some studies S. aureus were treated
with 100 mg/ml trypsin-EDTA for 30 minutes with constant
rotation, in order to remove cell wall proteins. Following this,
samples were centrifuged at 15,000 g for 5 min, then the
supernatant was removed and the pellet was re-suspended in
1 ml PBS. Trypsin-treated S. aureus were adjusted to 16109 cells/
ml for adhesion studies.
Bacterial strains and plasmids
S. aureus wildtype strains and mutants are listed in Table 1.
pCU1spa was constructed by amplifying DNA encoding the spa
gene including the promoter region and cloning into the multiple
cloning site. The region encoding the SpA IgG binding domains
EDABC was deleted by inverse PCR and an AccI site introduced
forming pCU1DspaDEDABC. The DNA region encoding the SpA
domains bearing an L17A substitution in each ligand binding
domain and flanked by AccI sites was synthesized commercially. It
was cut with AccI and cloned into the introduced AccI site in
pCU1DspaDEDABC. The resulting plasmid, pCU1spaL17A. was
verified by DNA sequencing.
Cell culture conditions
The mouse clonal MC3T3-E1 pre-osteoblastic cell line (ATCC,
Middlesex, UK) was used for these experiments. This is a standard
osteoblast cell line and is used routinely for the assessment of
osteoblasts in different culture conditions [42,43,44] These cells
were cultured in standard tissue culture flasks containing a-MEM
supplemented with 10% FBS, 2% penicillin-streptomycin solution
and 1% L-glutamine (Biosera Ltd., East Sussex, United Kingdom).
The media was replaced every 3–4 days and after confluency, cells
were harvested using trypsin and re-suspended in medium.
Osteoblast proliferation assay
Overnight cultures of S. auerus were harvested, washed and fixed
in 4.8% formaldehyde under rotation and washed to eliminate any
residual formaldehyde. S. aureus were centrifuged at 15,000 g for 5
minutes were re-suspended in a-MEM. A 6-well plate was coated
with 1 ml formaldehyde fixed S. aureus (16109 cell/ml) or 50 mg/
ml of purified protein A. The plate was incubated at 37uC with 5%
CO2 for 2hrs. Following this, the unbound bacteria or purified
protein A was removed by gentle aspiration. MC3T3-E1
osteoblasts (56105 cells/ml) were added into each well. Un-
infected osteoblasts were seeded and cultured in the absence of
bacteria as a control. Osteoblast proliferation was determined by
counting cells on a haemocytometer in a 1:1 dilution with Trypan
Blue.
Osteoblast binding studies
Microtitre plates (96 well) were coated with 100 ml of bacteria
(16109 cells/ml) or purified protein A (50 mg/ml) (Sigma, Wicklow,
Ireland). The plate was incubated at 37uC for 2 hours. Following
this, the plate was washed with PBS and blocked with 1% bovine
serum albumin (BSA) for a further 1 hour at 37uC. The plate was
then washed once in PBS to remove any unbound bacteria or
protein. MC3T3-E1 cells (1.56106 cells/ml) were added to each
well and allowed to adhere for 45 minutes at 37uC. In some studies,
osteoblasts were pre-incubated with 50 mg/ml of anti-TNFR-1
antibody or isotype control antibody (Santa Cruz, Heidelberg,
Germany) for 30 minutes at room temperature (RT) prior to their
addition to the plate. Each well was gently washed with 100 ml PBS
to remove any non-adhered osteoblasts. Adherent osteoblasts were
then lysed with 100 ml lysis buffer containing a substrate for acid
phosphatase (0.1 M Na acetate pH 5.5, 0.1% Triton X-100,
10 mM p-nitrophenol phosphate) and incubated for 20 minutes at
37uC and the A405nm read in a microplate reader (Wallac Victor2,
Perkin Elmer, Cambridge, United Kingdom).
Osteoblast apoptosis
Caspase 3 is a downstream effector caspase important in death
receptor apoptotic mechanisms. Caspase 3 activity was measured
using a Caspase 3 colorimetric assay kit (Clontech Laboratories,
Figure 7. Proposed model of Staphylococcus aureus – osteoblast
interaction.
doi:10.1371/journal.pone.0018748.g007
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CA (US) according to manufacturer’s instructions. Briefly,
cultured MC3T3-E1 osteoblasts were incubated with S. aureus or
purified protein A (50 mg/ml). Untreated osteoblasts were used as
a negative control and 100 mM dexamethasone- treated osteo-
blasts as a positive control. Cell lysates were incubated with the
Caspase 3 substrate DEVD-pNA at 37uC for 1 hour. Samples
were read at A 405nm in a microplate reader (Wallac Victor2,
Perkin Elmer, Cambridge, United Kingdom).
Annexin V-FITC staining to infected osteoblasts was carried out
according to the manufacturer guidelines (Trevigen). Cultured
MC3T3-E1 osteoblasts were infected over 24 h with 4.8%
formaldehyde fixed S. aureus Newman WT, NewmanDSpa and
Newman pCu1Spa (OD=1.6), un-infected osteoblasts were used
as negative control. Briefly un-infected and infected cells (1.56105)
were collected by centrifugation at 3006g for 5 min at RT. Pellets
were washed once in cold (4uC) PBS and re-centrifuged at 3006g
for 5 min at RT. Pellets were then re-suspended in 100 ml of
Annexin V Incubation Reagent. Suspensions were incubated in
the dark for 15 min at RT. Following addition of 400 ml of 1 X
Binding Buffer, samples were processed by flow cytometry.
Immunoblotting
S. aureus Newman (formaldehyde fixed or unfixed) were lysed in
RIPA buffer containing 1X protease inhibitor cocktail on ice for
10 minutes. Lysates were separated on a 10% sodium dodecyl-
sulfate polyacrylamide (SDS-PAGE) gel. Proteins were electro-
blotted onto polyvinyldifluoride membranes (Roche, UK) for 1 hr.
The membrane were probed with either a primary IgG antibody
(clone 3E8) or primary chicken anti-protein A IgY antibody (clone
SPA-27) overnight at 4uC with constant inversion. Unbound
antibody was removed by 3610 min washes with TS buffer.
Protein bands were detected using species-specific horseradish
peroxidase-conjugated secondary antibody and developed by
chemiluminescence.
Quantification of RANKL and OPG
MC3T3-E1 cells (16106 cells/well) were seeded on six well
plates. S. aureus was added to the osteoblasts for 24 hours. Two
hundred microlitres of the RIPA buffer was added to each well
resulting protein was removed and centrifuged at610,000 g for 2
minutes. RANKL or OPG was detected using an ELISA kit
(R&D Systems, Minneapolis, MN) according to manufacturer’s
instructions.
Statistical Analysis
Statistics were performed using SSC-Stat V2.12. Data shown
are the means plus or minus standard error of the mean (SEM).
Comparisons between mean values were performed using a 2-
tailed student T-test.
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